Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Goodchild

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|June 15, 2026
Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular DegenerationEslam Ahmed, Christine Goodchild, Anastasios Bisoukis, et al.
Eye (London, England)|May 15, 2020
5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitisChristine Goodchild, Micheal O'Rourke, Muhammad Haroon, et al.
Eye (London, England)|July 4, 2024
Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapyChristine Goodchild, Clare Bailey, Jimena Soto Hernaez, et al.
Transplantation|November 26, 2019
High-risk Corneal Transplantation: Recent Developments and Future PossibilitiesW John Armitage, Christine Goodchild, Matthew D Griffin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Clinical Ophthalmology (Auckland, N.Z.)|June 15, 2026
Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular DegenerationEslam Ahmed, Christine Goodchild, Anastasios Bisoukis, et al.
Eye (London, England)|May 15, 2020
5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitisChristine Goodchild, Micheal O'Rourke, Muhammad Haroon, et al.
Eye (London, England)|July 4, 2024
Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapyChristine Goodchild, Clare Bailey, Jimena Soto Hernaez, et al.
Transplantation|November 26, 2019
High-risk Corneal Transplantation: Recent Developments and Future PossibilitiesW John Armitage, Christine Goodchild, Matthew D Griffin, et al.
Pageof 1